Methyldopa supplement for resistant essential hypertension: a prospective randomized placebo control crossover study.

Background: Resistant hypertension is an important public health problem, its prevalence varies between 30 to 50 per cent. However, there is no definite recommendation for the treatment of resistant hypertension (HT).

Material And Method: A prospective randomized placebo control crossover study in resistant HT was designed to compare safety and efficacy between methyldopa 250 mg twice daily and placebo using ambulatory blood pressure monitoring.

Blood pressure response to antihypertensive agents related to baseline blood pressure.

Prevalence of white-coat hypertension varies approximately 20 per cent among mild hypertensives. When white-coat hypertensives are prescribed antihypertensive medication, there is usually a decrease in clinic blood pressure (BP), but little or no change in 24 hours blood pressure (ABPM). The objective of the study was to test the hypothesis that efficacy of medication therapy for hypertension is identical in any grading of severity of baseline blood pressure.